Evandro de Azambuja, MD, PhD, leads the Medical Support Team (Academic Promoting Team) at the Jules Bordet Institute in Brussels, Belgium. In this role, he oversees 4-5 research fellows and provides medical supervision for large phase III clinical trials, particularly in breast cancer.
Dr. de Azambuja holds two PhDs, one from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007, and another from the Université Libre de Bruxelles (U.L.B) in December 2015.
His primary focus in medical oncology is breast cancer, particularly in adjuvant/neoadjuvant settings. He actively participates in significant phase III trials, including HERA, ALTTO, APHINITY, Alexandra, Olympia, and the LORELEI trial focusing on PI3K inhibition in combination with endocrine therapy (Global PI). Dr. de Azambuja is also involved in studies on cancer drug toxicity and long-term follow-up of clinical trial patients, with a specific interest in cardiotoxicity.
During the COVID-19 pandemic, he played a crucial role in understanding the impact of COVID-19 on cancer patients, leading collaborations between BSMO and Sciensano. He initiated a prospective clinical trial on COVID-19 vaccine efficacy in cancer patients, actively recruiting in Belgium and soon in Portugal (I-SPARC).
Currently serving as ESMO Director of Membership, Dr. de Azambuja is on the ESMO Executive Board and Council. His extensive involvement with ESMO includes chairing the Fellowship Committee, being a faculty member of the Leaders Generation Programme, and serving on various committees. He has also contributed significantly to the field with numerous peer-reviewed articles and book chapters.
A member of ASCO and BSMO, Dr. de Azambuja is recognized for his editorial roles, previously with the Journal of Clinical Oncology (JCO) and currently with ESMO Open –Cancer Horizons. His expertise extends to reviewing for various oncology journals, and he has been an invited international speaker at numerous conferences worldwide.
